Immune Thrombocytopenia Clinical Trials

32 recruiting

Immune Thrombocytopenia Trials at a Glance

72 actively recruiting trials for immune thrombocytopenia are listed on ClinicalTrialsFinder across 6 cities in 33 countries. The largest study group is Phase 2 with 30 trials, with the heaviest enrollment activity in Tianjin, Beijing, and Tianjin. Lead sponsors running immune thrombocytopenia studies include Institute of Hematology & Blood Diseases Hospital, China, Peking University People's Hospital, and University Hospital, Bordeaux.

Browse immune thrombocytopenia trials by phase

Treatments under study

About Immune Thrombocytopenia Clinical Trials

Looking for clinical trials for Immune Thrombocytopenia? There are currently 32 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Immune Thrombocytopenia trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Immune Thrombocytopenia clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 72 trials

Recruiting
Phase 3

Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment

Immune Thrombocytopenia
Sanofi60 enrolled24 locationsNCT07007962
Recruiting
Phase 3

A Study to Assess the Efficacy and Safety of Efgartigimod IV in Adult Participants With Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
argenx69 enrolled94 locationsNCT06544499
Recruiting
Phase 4

Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults

Primary Immune Thrombocytopenia (ITP)
Institute of Hematology & Blood Diseases Hospital, China224 enrolled1 locationNCT04518475
Recruiting
Phase 3

High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Shandong University86 enrolled1 locationNCT07559331
Recruiting
Phase 2Phase 3

A Study of Efgartigimod IV in Participants From 12 Years to Less Than 18 Years of Age With Chronic Immune Thrombocytopenia (ITP)

Immune Thrombocytopenic PurpuraITPITP - Immune Thrombocytopenia+1 more
argenx24 enrolled8 locationsNCT07194850
Recruiting
Phase 1Phase 2

A Study of Pirtobrutinib in Participants With Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
Eli Lilly and Company58 enrolled45 locationsNCT06721013
Recruiting
Phase 2

Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders

Immune Thrombocytopenia
Incyte Corporation56 enrolled40 locationsNCT07104565
Recruiting
Phase 3

An Open-label Study of Intravenous Immunoglobulin (5%) for the Treatment of Primary Immune Thrombocytopenia

Primary Immune Thrombocytopenia (ITP)
Grand Shuyang Life Sciences (Chengdu) Co., Ltd.36 enrolled9 locationsNCT07233213
Recruiting
Phase 1

Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)

Antiphospholipid Syndrome (APS)Immune-mediated Necrotizing Myopathy (IMNM)Immune Thrombocytopenia (ITP)+3 more
Chugai Pharmaceutical144 enrolled69 locationsNCT06371417
Recruiting
Phase 1Phase 2

A Phase 1b/2a Study of Budoprutug in Subjects With Immune Thrombocytopenia (ITP)

ITPImmune Thrombocytopenia (ITP)Monoclonal+2 more
Climb Bio, Inc.24 enrolled20 locationsNCT07043946
Recruiting
Phase 3

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

Chronic Primary Immune Thrombocytopenia (ITP)
Kedrion S.p.A.40 enrolled27 locationsNCT07059000
Recruiting
Phase 1

Study of PN20 in Adult Patients With Primary Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)
Chongqing Peg-Bio Biopharm Co., Ltd.12 enrolled5 locationsNCT06880081
Recruiting
Phase 2

Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07234019
Recruiting
Phase 2

Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China160 enrolled1 locationNCT07297563
Recruiting
Not Applicable

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

ThrombocytopeniaImmune ThrombocytopeniaMyelodysplasia
University Hospital, Bordeaux225 enrolled1 locationNCT04800458
Recruiting
Phase 2

The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

Relapsed/Refractory Immune Thrombocytopenia
Seoul National University Hospital29 enrolled4 locationsNCT05599880
Recruiting
Phase 2

A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)

Immune Thrombocytopenia (ITP)
Dizal Pharmaceuticals60 enrolled1 locationNCT07294365
Recruiting
Phase 2

Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)

TreatmentImmune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China20 enrolled1 locationNCT07362199
Recruiting
Phase 3

V-IMMUNE® for Immune Thrombocytopenia

Immune Thrombocytopenia (ITP)
On Pharma Importadora, Exportadora e Distribuidora de Medicamentos LTDA.31 enrolled2 locationsNCT06962631
Recruiting
Phase 1Phase 2

A Phase Ib/II Clinical Trial of Multiple Doses of STSA-1301 Subcutaneous Injection in Healthy Subjects and Patients With Immune Thrombocytopenia (ITP)

Primary Immune Thrombocytopenia (ITP)
Jiangsu BioJeTay Biotechnology Co., Ltd.56 enrolled7 locationsNCT06929299